Currently, gadolinium-based agents are the standard in MRI for enhancing the visualization of tissues and organs. However, their use has raised several concerns related to gadolinium retention in body tissues, potential side effects in individuals with renal impairment, and ecological accumulation. To address these limitations, researchers have been exploring natural and biocompatible substitutes.
In this preclinical study, the team examined both betanin and BBCAs for their imaging performance, safety, and molecular characteristics. The work involved in vitro testing on human and mouse fibroblast cells, as well as in vivo experiments on 15 male Wistar albino rats and two male New Zealand albino rabbits. The MRI scans were conducted at 3-tesla field strength using spin echo and gradient echo sequences. Quantitative analyses were carried out using Microsoft Excel and GraphPad Prism 9.0.
The chemical properties of betanin and its derivative agents were analyzed through mass spectrometry, and their biological safety was evaluated using cytotoxicity assays, flow cytometry, histological assessments, and blood biochemistry tests. The agents were administered orally, intraperitoneally, and intravenously to assess their effects across different exposure routes.
The study yielded several noteworthy observations:
- Betanin exhibited stronger molecular binding efficiency and higher therapeutic potential than conventional agents.
- BBCAs demonstrated significantly lower toxicity compared to gadobutrol, a commonly used GBCA.
- Both betanin and BBCAs produced visible contrast enhancement in the gastrointestinal tract, parenchymal organs, and vascular structures, indicating effective imaging capability.
- The agents also showed antioxidative properties and a favorable safety profile, making them attractive candidates for further research.
- Notably, liver enhancement following BBCA administration was particularly prominent.
The researchers concluded that betanin and BBCA could be viable candidates for contrast-enhanced abdominal MRI, offering diagnostic clarity comparable to existing agents but with a potentially reduced risk profile.
While these findings are encouraging, the authors emphasized that this was a preliminary preclinical study, and more extensive research in clinical settings is needed to confirm the efficacy, optimal dosing, and long-term safety of betanin-based agents.
"Overall, this investigation opens an exciting avenue in MRI technology, pointing toward natural, biocompatible contrast agents that could one day replace gadolinium-based formulations, enhancing patient safety and environmental sustainability," the authors wrote.
Reference:
Özsunar, Y., Kayhan, H., Kurt, B., Esen, A. C., Aktaş, S., Tataroğlu, C., & Bilgen, M. Betanin-Based Contrast Agents for MRI: A Preliminary Experimental Study. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.70158
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.